Report cover image

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 193 Pages
SKU # APRC20561142

Description

Summary

According to APO Research, The global Proliferative Vitreoretinopathy (PVR) Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics include Novartis AG, RXi Pharmaceuticals Corp and Promedior Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Proliferative Vitreoretinopathy (PVR) Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Proliferative Vitreoretinopathy (PVR) Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for Proliferative Vitreoretinopathy (PVR) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Proliferative Vitreoretinopathy (PVR) Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Proliferative Vitreoretinopathy (PVR) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Proliferative Vitreoretinopathy (PVR) Therapeutics sales, projected growth trends, production technology, application and end-user industry.

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Company

Novartis AG
RXi Pharmaceuticals Corp
Promedior Inc
Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Type

PRM-167
XOMA-089
Others
Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Application

Clinic
Hospital
ASCs
Others
Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Proliferative Vitreoretinopathy (PVR) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proliferative Vitreoretinopathy (PVR) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Proliferative Vitreoretinopathy (PVR) Therapeutics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Proliferative Vitreoretinopathy (PVR) Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Proliferative Vitreoretinopathy (PVR) Therapeutics sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Type
1.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 PRM-167
1.2.3 XOMA-089
1.2.4 Others
1.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Application
1.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinic
1.3.3 Hospital
1.3.4 ASCs
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Dynamics
2.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends
2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers
2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges
2.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints
3 Global Market Growth Prospects
3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Estimates and Forecasts (2020-2031)
3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region
3.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2020-2025)
3.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2026-2031)
3.2.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2020-2031)
3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Estimates and Forecasts 2020-2031
3.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region
3.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2020-2025)
3.4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2026-2031)
3.4.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers
4.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (2020-2025)
4.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers
4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers (2020-2025)
4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Price by Manufacturers (2020-2025)
4.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers, Product Type & Application
4.7 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market CR5 and HHI
4.8.2 2024 Proliferative Vitreoretinopathy (PVR) Therapeutics Tier 1, Tier 2, and Tier 3
5 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Type
5.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type
5.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2020-2031)
5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type
5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2031) & (k units)
5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2020-2031)
5.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type
6 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Application
6.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application
6.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2020-2031)
6.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application
6.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2031) & (k units)
6.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2020-2031)
6.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application
7 Company Profiles
7.1 Novartis AG
7.1.1 Novartis AG Comapny Information
7.1.2 Novartis AG Business Overview
7.1.3 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
7.1.5 Novartis AG Recent Developments
7.2 RXi Pharmaceuticals Corp
7.2.1 RXi Pharmaceuticals Corp Comapny Information
7.2.2 RXi Pharmaceuticals Corp Business Overview
7.2.3 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
7.2.5 RXi Pharmaceuticals Corp Recent Developments
7.3 Promedior Inc
7.3.1 Promedior Inc Comapny Information
7.3.2 Promedior Inc Business Overview
7.3.3 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
7.3.5 Promedior Inc Recent Developments
8 North America
8.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
8.1.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2031)
8.1.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2031)
8.1.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2020-2031)
8.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
8.2.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2031)
8.2.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2031)
8.2.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2020-2031)
8.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
8.3.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
9.1.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2031)
9.1.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2031)
9.1.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2020-2031)
9.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
9.2.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2031)
9.2.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2031)
9.2.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2020-2031)
9.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
9.3.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
9.3.9 Nordic Countries
10 China
10.1 China Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
10.1.1 China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2031)
10.1.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2031)
10.1.3 China Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2020-2031)
10.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
10.2.1 China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2031)
10.2.2 China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2031)
10.2.3 China Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
11.1.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2031)
11.1.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2031)
11.1.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2020-2031)
11.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
11.2.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2031)
11.2.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2031)
11.2.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2020-2031)
11.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
11.3.1 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
12.1.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2020-2031)
12.1.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2020-2031)
12.1.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Type (2020-2031)
12.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
12.2.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2020-2031)
12.2.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2020-2031)
12.2.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2020-2031)
12.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
12.3.1 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Analysis
13.1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process
13.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors
13.2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.